(adds details in last 3 paragraphs)
MOSCOW, Oct 15 (PRIME) -- The post-registration trial of the coronavirus vaccine EpiVacCorona will start after mass production of the vaccine, an official of the Federal Service for Consumer Rights Protection and Human Welfare Oversight said on Thursday.
"The Novosibirsk center Vector will start a multi-center clinical trial with 40,000 volunteers after industrial volumes of the registered vaccine are produced," the statement read.
President Vladimir Putin said on Wednesday that Russia registered a second vaccine for the coronavirus produced by the Vector State Center for Virology and Biotechnology (Vector Institute).
Healthcare Minister Mikhail Murashko said that the vaccine has some advantages over Sputnik V.
“It is built on a different technology. It will give us an arsenal to produce the vaccines because the technological cycle is a bit easier," Murashko said.
He also said that the amount of coronavirus vaccine supplies is to rise in November–December.
End %%mk/jst%%
|
|
